IMTX News & Events

Immatics announced the presentation of extended data from the ongoing Phase 1 clinical trial evaluating its TCR bispecific candidate IMA401 targeting MAGEA4/8 in heavily pretreated patients with solid tumors, including head and neck cancer and lung cancer, in an oral presentation at the Annual Meeting of the American Society for Clinical Oncology, ASCO, in Chicago, IL, USA. Results from the Phase 1 study are being published simultaneously in Nature Medicine. Key data: IMA401 achieved deep and durable responses in various indications, including melanoma and head and neck cancer, with an initial promising clinical signal observed in lung cancer; In head and neck cancer, IMA401 treatment at recommended Phase 2 dose with or without pembrolizumab resulted in a 29% confirmed ORR, 64% DCR and mDOR of 8.8 months; all responders achieved deep responses with 60-100% tumor reduction; IMA401 MAGEA4/8 TCR bispecific demonstrated favorable tolerability at RP2D with or without pembrolizumab, suggesting its potential for broad combinability; IMA401 data will be presented in an oral presentation at the 2026 ASCO Annual Meeting and published simultaneously in Nature Medicine; The data support Immatics' strategy to combine IMA401 with IMA402 in lung cancer and potentially other indications, where the combined target prevalence supports broad patient coverage and potential synergistic activity; the IMA401/IMA402 combination cohort is now enrolling at multiple clinical trial sites, with first data expected in 2027

Immatics N.V. announced updated Phase 1 data for its IMA203CD8 PrameTCR T-cell therapy in gynecologic cancers and synovial sarcoma at the Annual Meeting of the American Society for Clinical Oncology, ASCO, in Chicago, IL, USA. One-time infusion of IMA203CD8 demonstrated meaningful clinical activity across different tumor types as well as manageable tolerability. The broad expression of PRAME in more than 50 cancers further supports the continued development of IMA203CD8 in multiple PRAME-positive solid tumors. IMA203CD8 demonstrated a manageable and consistent tolerability profile across patient populations. Clinical anti-tumor activity observed across tumor types with distinct biology and differing levels of PRAME expression, including lower PRAME levels in ovarian carcinoma. Clinical profile of IMA203CD8 supports continued development in gynecologic cancers and expansion into other PRAME-positive solid tumors. Determination of recommended phase 2 dose remains expected in 2026

Reports Q1 revenue $7.61M, consensus $10.41M. "Immatics is entering a pivotal period as we continue to progress toward the pre-specified interim and final analyses from the Phase 3 SUPRAME trial of anzu-cel and actively prepare for commercialization in 2027," said Harpreet Singh, Chief Executive Officer and Co-Founder of Immatics. "At the same time, we expect multiple meaningful clinical readouts across our PRAME franchise in 2026 that continue to validate PRAME as an important target across multiple solid cancers, extending well beyond melanoma, and across two different therapeutic modalities. Immatics today is a company defined not only by compelling science, but by a diversified late- and mid-stage clinical portfolio, growing commercial readiness, and a clear strategy to translate innovation into meaningful patient impact."